Jaguar Animal Health (NASDAQ:JAGX) Posts Earnings Results, Beats Expectations By $135.50 EPS

Jaguar Animal Health (NASDAQ:JAGX) posted its earnings results on Wednesday. The biotechnology company reported ($13.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($149.10) by $135.50, FiscalAI reports. The firm had revenue of $20.27 million for the quarter, compared to analyst estimates of $4.21 million. Jaguar Animal Health had a negative net margin of 464.20% and a negative return on equity of 1,194.94%.

Jaguar Animal Health Stock Up 9.2%

JAGX stock traded up $0.31 during midday trading on Wednesday, reaching $3.67. 29,978 shares of the company’s stock traded hands, compared to its average volume of 93,845. Jaguar Animal Health has a 52 week low of $2.53 and a 52 week high of $186.55. The company has a market cap of $1.37 million, a price-to-earnings ratio of -0.00 and a beta of 0.01. The firm’s fifty day moving average price is $11.69 and its 200-day moving average price is $28.22. The company has a quick ratio of 0.29, a current ratio of 0.50 and a debt-to-equity ratio of 4.08.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Wall Street Zen raised shares of Jaguar Animal Health from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.